XML 18 R9.htm IDEA: XBRL DOCUMENT
v3.22.1

Inventory | 3 Months Ended
--- | ---
Mar. 31, 2022
Inventory Disclosure [Abstract] |
Inventory | Inventory Inventory includes unprocessed tissue, work-in-process, Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard Nerve Cap®, and Axotouch® Two-Point Discriminator finished goods and supplies. Inventory is valued at the lower of cost (first-in, first-out) or net realizable value and consists of the following:
(In thousands) | March 31, 2022 |  | December 31, 2021
Finished goods | $ | 11,856 |  |  | $ | 11,011 |
Work in process | 851 |  |  | 813 |
Raw materials | 4,693 |  |  | 4,869 |
Inventory | $ | 17,400 |  |  | $ | 16,693 |
The provision for inventory write-downs was $459 and $783 for the three months ended March 31, 2022, and 2021, respectively.

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -URI http://asc.fasb.org/topic&trid=2126998 + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration